Endo for recombinant human vascular endothelial inhibitor, the treatment of pleural effusion generally requires 2 to 4 treatment cycles to be able to play a role, depending on the severity of the disease and the patient’s personal constitution. Recombinant human vascular endothelial inhibitor, can treat certain malignant pleural effusion, reperfusion treatment of the pleural cavity of the patient, inhibit the regrowth of tumors in the thoracic cavity, so that the reduction of tumor cells, but also effectively prevent the formation and recurrence of malignant pleural effusion, generally need to be treated for 2 to 4 cycles, depending on the patient’s personal situation. Some people may have adverse cardiac reactions and digestive system reactions, etc., and may experience symptoms such as chest tightness, nausea, vomiting, etc. The symptoms are usually not obvious and can be relieved after the drug is discontinued. Patients are advised to go to the hospital in time.